Navigation Links
Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
Date:6/20/2011

SAN DIEGO, June 20, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced three upcoming data presentations for it Ultrafast Insulin programs at the American Diabetes Association (ADA) 71st Scientific Sessions taking place June 24-28, 2011 at the San Diego Convention Center.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentations include a late-breaking abstract on the safety and efficacy of Aspart-PH20, a formulation of Halozyme's rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog®, administered via continuous pump infusion in type 1 diabetes patients over three days. A second presentation tests the safety and evaluates whether regular insulin can be made as fast as an analog. The presentations are scheduled as follows:

Oral Presentation
Saturday – June 25, 2011
1:45 – 2:00 p.m.: Comparison of Human Hyaluronidase + Recombinant Human Insulin (RHI) vs. Insulin Lispro in a Basal-Bolus Regimen in Patients with Type 1 Diabetes (T1DM)
Abstract Number: 0069-OR
Presented during session: Pharmacologic Treatment of Diabetes-Insulin Therapy

Late Breaker Poster – Insulin Pump Study
Sunday – June 26, 2011
12:00 – 2:00 p.m.: Addition of Human Hyaluronidase to Rapid Analog Insulin Reduces the Absolute Variability of Early Insulin Absorption across Infusion Set Life
Abstract Number: 0027-LB
Location: Hall B – Poster Hall

Poster
Sunday – June
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Ontario (PRWEB) May 21, 2013 ... scientists of the ITN to design the study, ... of two key clinical models used in the ... (EEC) and Nasal Allergen Challenge (NAC) models. Although ... by numerous publications, to date no direct comparison ...
(Date:5/21/2013)... Possible mold re-infestation in Guilemtte School sparked ... report from eagletribune.com posted May 14, 2013, the state is ... is positive, My Cleaning Products offered a tip how ... It was said in the Eagle Tribune report (5.14.13) that ... sparked after a first-grade classroom was closed due to the ...
(Date:5/21/2013)... PathoGenetix, Inc., a commercial-stage developer of an automated ... it has successfully identified and strain typed a collection ... Centers for Disease Control and Prevention (CDC) using the ... detailed in a poster presented at the ... Denver on Monday. , The 250 E. coli strains, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Clinovo's ... an 8-week training program starting on June 11th, 2013. ... clinical trial professionals reach the next step in their ... Offices in Palo Alto, and streamed online. , Taught ... award-winning papers, Clinovo's new “CDISC Standards: Theory and Application” ...
Breaking Biology Technology:Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Clinovo Launches TechTrainings on CDISC Standards 2
... Calif. and BANGALORE, India, July 10, 2011 Life ... that it has launched a regional distribution hub in India ... The new India Distribution Center (IDC), located ... of Life Technologies, products to its thousands of customers in ...
... NATICK, Mass., July 8, 2011 RegenoCELL Therapeutics, Inc. (OTCBB: ... pleased to announce the opening of another state of the ... congestive heart failure and peripheral artery disease with its autologous ... congestive heart failure is administered at the Metropolitan Hospital in ...
... Care Compliance Strategies, Inc. (HCCS) announced today a partnership ... to deliver a series of critical care nursing and ... Management Systems.  This training includes two separate AACN courses: ... Essentials of Nurse Manager Orientation . The courses ...
Cached Biology Technology:Life Technologies Launches New Distribution Center in India 2Life Technologies Launches New Distribution Center in India 3RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece 2RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece 3HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training 2HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training 3
(Date:5/20/2013)... MINNEAPOLIS/ST. PAUL (MAY 20, 2013) University of Minnesota ... of Minnesota, in partnership with the University,s Brain Tumor ... peripheral nerve sheath tumors (MPNST) that allow them to ... of cancer. , The research was published this week ... the Sleeping Beauty transposon method, researchers in the lab ...
(Date:5/20/2013)... New research suggests that a compound abundant in the ... death. , By altering a very specific step ... into normal cells that die as scheduled. , One ... process that would cause them to die on a ... study in cells, led by Ohio State University researchers, ...
(Date:5/20/2013)... study conducted at the University of Bristol and published ... sheds light on how the brain and inner ... Bristol,s School of Earth Sciences, together with Tom Hbner ... brains of 150 million year old dinosaurs. , The ... Dysalotosaurus lettowvorbecki : a very young (juvenile) individual ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3Fossil brain teaser 2
... University of Santiago de Compostela (USC) have studied the ... show that the principal goal of young people is ... antisocial among them place greater importance on popularity with ... on are to do with leaving home, work and ...
... ulcers, one of the ,neglected tropical diseases, left aside by ... in poor regions. But then more attention has to be ... rules of the World Health Organization urgently need to be ... Medicine (ITM), based on ten years of research in Congo. ...
... This release is available in Spanish . ... receive--in addition to what foods you eat--all can influence the ... for optimum health. In a preliminary and apparently first-of-its-kind study, ... colleagues have developed a preliminary model that predicts an individual,s ...
Cached Biology News:Teenagers want to finish their studies and leave home 2WHO guidelines on Buruli ulcer need adjustment 2Model predicts individual's vitamin D needs 2
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
...
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Request Info...
Biology Products: